Fairvalue-Calculator Fairvalue-Calculator
EN DE

Epigenomics AG (EPGNF) Fair Value & Analysis

Healthcare · US · Market cap $982K

Price$1.12
Fair Value$1.05
Upside-5.9%
Quality95/100
Evidence: Low Range $0.8283 – $1.28

Fair value as of: Jun 25, 2026

Analysis

Epigenomics AG (EPGNF) currently trades at $1.12, while our model-based Fair Value estimate is $1.05 — implying the stock looks roughly 5.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Heidelberg, Germany.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -54% Danaher Corporation (DHR) -54% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -77% Agilent Technologies, Inc (A) -52%

Frequently asked questions

Is Epigenomics AG (EPGNF) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.05 versus a price of $1.12 — about −6% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EPGNF?
Our 21-model fair value for Epigenomics AG is $1.05 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.12.
What is the quality score of EPGNF?
Epigenomics AG has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.